|
Press Releases |
|
|
|
Monday, April 12, 2021 |
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
Wednesday, March 31, 2021 |
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
Tuesday, March 30, 2021 |
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩(製品名:「レンビマ(R)」、「Kisplyx(R)」、以下 レンバチニブ)について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)の抗PD-1抗体ペムブロリズマブ(製品名:「キイトルーダ(R)」、以下 ペムブロリズマブ)との併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る適応追加の申請をそれぞれ行い、欧州医薬品庁によって受理されましたのでお知らせします。 more info >> |
|
Friday, March 26, 2021 |
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
Tuesday, March 23, 2021 |
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
エーザイとMSD、「レンビマ(R)」(レンバチニブ)について日本において「切除不能な胸腺癌」の効能効果の承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とMerck & Co., Inc., Kenilworth, N.J., U.S.A.の日本法人であるMSD株式会社(本社:東京都千代田区、代表取締役社長: カイル・タトル、以下 MSD)は、本日、エーザイ創製のマルチキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)について、日本において「切除不能な胸腺癌」の効能効果追加の承認を取得したことをお知らせします。本剤は、日本における「切除不能な胸腺癌」に対する初めての承認薬剤となります。 more info >> |
|
Monday, March 22, 2021 |
|
エーザイ、川島工園において新注射剤棟/研究棟新築工事に着工 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、本日、当社の中期経営計画EWAY2025実現に向けた戦略投資の一環として、川島工園(岐阜県)において、新注射剤棟/研究棟(名称:Eisai Medicine Innovation Technology Solutions、以下 EMITS)建設の起工式を実施したことをお知らせします。 more info >> |
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
AdSure Invites Advertisers to Access Top-Quality Finance and Insurance Leads - 10% Conversion Guarantee for Top Funnel Live Leads
Nov 7, 2024 23:00: JST
|
|
|
AdSure Invites Advertisers to Access Top-Quality Finance and Insurance Leads - 10% Conversion Guarantee for Top Funnel Live Leads
Nov 7, 2024 22:00 HKT/SGT
|
|
|
The 16th Hong Kong International Wine & Spirits Fair kicks off today
Nov 7, 2024 21:13: JST
|
|
|
CNNICがグローバルマーケティング担当者を対象にブランド調査を実施
Nov 7, 2024 21:00: JST
|
|
|
The 16th Hong Kong International Wine & Spirits Fair kicks off today
Nov 7, 2024 20:13 HKT/SGT
|
|
|
Three Ways AI Tools Can Help Drive Efficiencies for Small Businesses
Nov 7, 2024 19:36: JST
|
|
|
Three Ways AI Tools Can Help Drive Efficiencies for Small Businesses
Nov 7, 2024 18:36 HKT/SGT
|
|
|
Selayang Mall Environment Week 2024 Unites Community for a Greener Future
Nov 7, 2024 18:00 HKT/SGT
|
|
|
Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field
Nov 7, 2024 18:19 JST
|
|
|
Dr. Friend Proposes the Potential for Non-Pharmacological Improvement of Sleep Disorders, Published in an International SCI-Level Journal
Nov 7, 2024 16:30: JST
|
|
|
Mitsubishi Motors Acquires Its Own Shares from Nissan
Nov 7, 2024 17:20 JST
|
|
|
Honda Signs Sponsorship Agreement to Provide Electrified Vehicles at World Athletics Championships Tokyo 25
Nov 7, 2024 17:10 JST
|
|
|
International Scam Losses Over US $1 Trillion in 12 Months as Scams Continue to Plague Consumers
Nov 7, 2024 16:00 HKT/SGT
|
|
|
GTJAI Wins Four Major Awards from WIND for Best Investment Bank of 2023
Nov 7, 2024 15:59 HKT/SGT
|
|
|
國泰君安國際榮獲萬得Wind 2023年度最佳投行四項大獎
Nov 7, 2024 15:55 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|